Dr Gereon Heinemann, CEO of Exentis Group AG, will give his presentation at the specialist congress on the topic of "New paths in pharmaceutical production and galenics - serial multi-active ingredient tablet production"
What does additive manufacturing have in common with galenics? With its comprehensively patented additive manufacturing technology, Exentis can print tablets with completely new properties and a freely selectable active ingredient release profile. Imagine a multi-active ingredient production process that allows the manufacture of tablets in which the release of the individual active ingredients is staggered. This is what we mean by innovation: a combination of our 3D screen printing technology and direct added value for the individual patient.
Exentis has optimised its additive manufacturing technology for any cleanroom application in a modular system for pharmaceutical applications. This allows up to 3 different active ingredients to be processed on one system and up to 200 million tablets to be produced per year. A first cleanroom system was successfully installed and commissioned at a CDMO in April 2024 - find out for yourself what is possible with Exentis systems.
Presentation language: GER
(English translation will be provided on site)
